Autolus Therapeutics
AUTL
48 hedge funds and large institutions have $241M invested in Autolus Therapeutics in 2018 Q2 according to their latest regulatory filings, with 48 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
22.89% more ownership
Funds ownership: 0% → 22.89% (+23%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WIM
Woodford Investment Management
London,
United Kingdom
|
+$42.1M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$40.3M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$29.1M |
| 4 |
AI
Alphabet Inc
Mountain View,
California
|
+$18.9M |
| 5 |
AG
Artal Group
Luxembourg
|
+$13.9M |
Top Sellers
AUTL Hedge Fund Activity: Q2 2018 in Review
48 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q2 2018, worth a combined $241M.
Buyers outnumbered sellers: 48 funds opened new AUTL positions and 0 closed out — a net gain of 48 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Woodford Investment Management, opening a new position worth an estimated $42.1M.
- 48 institutional investors held Autolus Therapeutics (AUTL) as of Q2 2018, up from 0 in Q1 2018.
- Funds reported $241M of Autolus Therapeutics stock for Q2 2018.
- 48 funds opened new Autolus Therapeutics positions in Q2 2018 and 0 closed out, a net change of +48 holders.
- The largest Autolus Therapeutics buyer in Q2 2018 was Woodford Investment Management, an estimated $42.1M added.
Based on aggregated 13F filings for Q2 2018.